Search

Your search keyword '"De Placido S"' showing total 17 results
Start Over Author "De Placido S" Publisher american society of clinical oncology (asco)
17 results on '"De Placido S"'

10. Residual neurotoxicity in patients with ovarian cancer in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trials in Ovarian cancer (MITO-4) retrospective study

Author

Di Maio, M., primary, Iaffaioli, R. V., additional, de Placido, S., additional, Biamonte, R., additional, Scambia, G., additional, Di Vagno, G., additional, Febbraro, A., additional, Colucci, G., additional, Pisano, C., additional, and Pignata, S., additional

Published
2005
Full Text
View/download PDF

13. Chemotherapy-induced cardiotoxicity: An animal model

Author

Romano, C., primary, Marinelli, A., additional, Fortunato, F., additional, Adinolfi, L., additional, Salvatore, G., additional, Ciarcia, R., additional, Russo, F., additional, Cuda, G., additional, De Placido, S., additional, and Bianco, A. R., additional

Published
2004
Full Text
View/download PDF

15. Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole.

Author

Gridelli, C, primary, Perrone, F, additional, Ianniello, G P, additional, Brancaccio, L, additional, Iaffaioli, R V, additional, Curcio, C, additional, D'Aprile, M, additional, Cioffi, R, additional, Cigolari, S, additional, Rossi, A, additional, Palazzolo, G, additional, Veltri, E, additional, Pergola, M, additional, De Placido, S, additional, Gallo, C, additional, Monfardini, S, additional, and Bianco, A R, additional

Published
1998
Full Text
View/download PDF

17. Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study

Author

Luigi Manzione, Andrea de Matteis, Emanuele Naglieri, R. Biamonte, Giovanni Scambia, Gianpietro Gasparini, Marco Marinaccio, Stefano Greggi, Giacomo Cartenì, Rossella Lauria, Sabino De Placido, Antonio Febbraro, Alessandra Vernaglia Lombardi, S. Danese, Francesco Perrone, Maria Rosaria Valerio, Michele De Laurentiis, Giovanni Di Vagno, Sandro Pignata, Ciro Gallo, DE PLACIDO, S, Scambia, G, DI VAGNO, G, Naglieri, E, Lombardi, Av, Biamonte, R, Marinaccio, M, Carten, G, Manzione, L, Febbraro, A, DE MATTEIS, A, Gasparini, G, Valerio, Mr, Danese, S, Perrone, F, Lauria, R, DE LAURENTIIS, M, Greggi, S, Gallo, Ciro, Pignata, S., DE PLACIDO, Sabino, Carteni, G, Lauria, Rossella, DE LAURENTIIS, Michelino, and Gallo, C

Subjects
Adult, Cancer Research, medicine.medical_specialty, Neutropenia, Randomization, Paclitaxel, medicine.medical_treatment, Disease-Free Survival, Carboplatin, law.invention, chemistry.chemical_compound, Randomized controlled trial, law, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Infusions, Intravenous, Aged, Ovarian Neoplasms, Chemotherapy, business.industry, Area under the curve, Middle Aged, medicine.disease, Antineoplastic Agents, Phytogenic, Thrombocytopenia, Surgery, Treatment Outcome, Oncology, chemistry, Area Under Curve, Female, Topotecan, Ovarian cancer, business, medicine.drug
Abstract

Purpose Topotecan is an active second-line treatment for advanced ovarian cancer. Its efficacy as consolidation treatment after first-line standard chemotherapy is unknown. Patients and Methods To investigate whether topotecan (1.5 mg/m2 on days 1 through 5, four cycles, every 3 weeks) prolonged progression-free survival (PFS) for patients responding to standard carboplatin (area under the curve 5) and paclitaxel (175 mg/m2 administered as a 3-hour infusion in six cycles; CP), a multicenter phase III study was performed with an 80% power to detect a 50% prolongation of median PFS. Patients were registered at diagnosis and randomized after the end of CP. Results Two hundred seventy-three patients were randomly assigned (topotecan, n = 137; observation, n = 136), with a median age of 56 years. Stage at diagnosis was advanced in three fourths of patients (stage III in 65% of patients; stage IV in 10%); after primary surgery, 46% had no residual disease and 20% were optimally debulked. After CP, 87% reached a clinical complete response, and 13% achieved a partial response. Neutropenia (grade 3/4 in 58% of the patients) and thrombocytopenia (grade 3 in 21%; grade 4 in 3%) were the most frequent toxicities attributed to topotecan. There was no statistically significant difference in PFS between the arms (P = .83; log-rank test): median PFS was 18.2 months in the topotecan arm and 28.4 in the control arm. Hazard ratio of progression for patients receiving topotecan was 1.18 (95% CI, 0.86 to 1.63) after adjustment for residual disease, interval debulking surgery, and response to CP. Conclusion The present analysis indicates that consolidation with topotecan does not improve PFS for patients with advanced ovarian cancer who respond to initial chemotherapy with carboplatin and paclitaxel.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results